HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Directives From House Range From Antibiotics To Zohydro

This article was originally published in The Pink Sheet Daily

Executive Summary

Draft appropriations committee report instructs FDA to undertake tasks both profound (offer a better accounting of how user fees are spent) and routine (meet with patient communities for specific diseases).

Advertisement

Related Content

Dalvance Approval Is Durata’s GAIN: First Test Of FDA’s Antibiotics Incentives
FDA Secure Supply Chain Pilot Draws Small Group, But Could Serve Globalization Goals
Drug Shortage Analysis Puts FDA At Loggerheads With GAO
FDA Makes It Formal, Rescinds SPA For Amarin’s ANCHOR Study
FDA Flexible With Accelerated Approval Evidence, Analysis Finds
FDA Accelerated Approval For Rare Diseases Again Under Congressional Pressure
Drug Shortages Mostly FDA’s Fault, House Oversight Committee Concludes

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077262

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel